SMMT

Summit Therapeutics Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.69
52-Week Range: $12.07 – $29.23
Market Cap: $13.37B
P/E (TTM): —
EPS (TTM): -1.11
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 21.10
PEG Ratio: —
Return on Equity: -192.50%
Return on Assets: -101.61%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.96
Debt/Equity: 0.03
Total Debt: $20.38M
Free Cash Flow: $-139.68M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $12.70B

SMMT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$705.00K	$0.00	$0.00	$0.00
Research & Development	$52.00M	$59.47M	$150.78M	$537.67M
Selling, General & Admin	$26.74M	$29.26M	$60.20M	$556.70M
Operating Expenses	$64.33M	$88.73M	$210.98M	$1.09B
Operating Income	-$63.62M	-$88.73M	-$210.98M	-$1.09B
EBITDA	-$73.12M	-$598.27M	-$212.53M	-$1.08B
Pretax Income	-$78.78M	-$614.93M	-$221.30M	-$1.08B
Net Income	-$78.78M	-$614.93M	-$221.31M	-$1.08B
Diluted EPS	-0.41	-0.99	-0.31	-1.44
Diluted Shares	193.34M	619.65M	718.54M	747.70M

SMMT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$348.61M	$71.42M	$104.86M	$225.27M
Receivables	$6.12M	$848.00K	$557.00K	—
Current Assets	$656.71M	$189.71M	$423.75M	$720.30M
Total Assets	$664.17M	$202.95M	$435.56M	$751.18M
Current Liabilities	$38.78M	$20.41M	$41.73M	$72.99M
Long-Term Debt	$494.54M	$100.00M	—	—
Total Debt	$518.76M	$106.10M	$7.22M	$20.89M
Total Liabilities	$537.51M	$125.26M	$46.81M	$92.32M
Retained Earnings	-$378.33M	-$993.26M	-$1.21B	-$2.29B
Shareholders' Equity	$126.65M	$77.69M	$388.75M	$658.86M
Working Capital	$617.93M	$169.31M	$382.02M	$647.31M
Net Debt	$165.70M	$28.57M	—	—

SMMT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$41.58M	-$76.76M	-$142.11M	-$322.93M
Capital Expenditure	-$624.00K	-$128.00K	-$139.00K	-$657.00K
Free Cash Flow	-$42.21M	-$76.89M	-$142.25M	-$323.59M
Depreciation & Amortisation	$1.26M	$198.00K	$89.00K	$146.00K
Stock-Based Compensation	$11.95M	$14.11M	$50.98M	$732.42M
Investing Cash Flow	-$624.00K	-$587.77M	-$205.34M	-$174.31M
Financing Cash Flow	$620.24M	$86.51M	$381.23M	$617.53M
Net Change in Cash	$578.04M	-$578.02M	$33.78M	$120.29M

SMMT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$208.02M	$131.10M	$147.29M	$132.62M	$157.73M
Selling, General & Admin	$360.42M	$103.11M	$77.58M	$62.59M	$62.76M
Operating Expenses	$568.44M	$234.21M	$224.88M	$195.21M	$220.50M
Operating Income	-$568.44M	-$234.21M	-$224.88M	-$195.21M	-$220.50M
EBITDA	-$568.40M	-$231.75M	-$219.08M	-$195.17M	-$220.45M
Pretax Income	-$565.71M	-$231.79M	-$219.12M	-$189.42M	-$215.70M
Net Income	-$565.71M	-$231.79M	-$219.17M	-$189.42M	-$215.70M
Diluted EPS	-0.76	-0.31	-0.29	-0.24	-0.28
Diluted Shares	742.62M	743.42M	766.40M	775.46M	778.18M

SMMT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$297.87M	$238.55M	$225.27M	$106.52M	$419.37M
Current Assets	$309.24M	$246.47M	$720.30M	$616.60M	$720.58M
Total Assets	$324.04M	$261.73M	$751.18M	$647.86M	$752.18M
Current Liabilities	$60.33M	$64.93M	$72.99M	$83.27M	$103.57M
Total Debt	$5.55M	$5.43M	$20.89M	$20.04M	$20.38M
Total Liabilities	$64.60M	$69.47M	$92.32M	$101.92M	$122.20M
Retained Earnings	-$1.84B	-$2.07B	-$2.29B	-$2.48B	-$2.70B
Shareholders' Equity	$259.44M	$192.26M	$658.86M	$545.93M	$629.98M
Working Capital	$248.91M	$181.54M	$647.31M	$533.33M	$617.01M

SMMT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$66.74M	-$93.08M	-$101.94M	-$122.29M	-$141.12M
Capital Expenditure	—	-$71.00K	-$164.00K	-$245.00K	-$909.00K
Free Cash Flow	-$66.74M	-$93.15M	-$102.10M	-$122.54M	-$142.03M
Depreciation & Amortisation	$37.00K	$42.00K	$42.00K	$44.00K	$46.00K
Stock-Based Compensation	$478.78M	$130.76M	$111.78M	$72.79M	$68.71M
Investing Cash Flow	$150.81M	-$71.00K	-$485.16M	-$238.00K	$222.90M
Financing Cash Flow	$2.22M	$33.81M	$573.82M	$3.80M	$231.08M
Net Change in Cash	$86.29M	-$59.34M	-$13.27M	-$118.73M	$312.85M

Market Snapshot

About

Summit Therapeutics Inc. is a biopharmaceutical company focused on developing innovative antibiotics and precision medicines for serious infectious diseases and oncology. The company is advancing ivonescimab, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. Summit is conducting global clinical trials to address antibiotic-resistant infections and difficult-to-treat cancers.